| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The unlabeled parent drug, Ropivacaine, targets voltage-gated sodium channels in nerve fibers, reversibly blocking sodium influx and thereby preventing nerve impulse propagation and signal transmission. It is a potent and selective blocker of these channels, used as a local anesthetic during surgery, childbirth, and for postoperative pain management.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers that influence measurement during the drug development process. It's possible that the pharmacokinetics and functional range of medications contribute to the concern over mutagenesis [1].
The labeled compound, Ropivacaine-d7 hydrochloride, exhibits identical pharmacological activity to the unlabeled parent drug, as the deuterium label does not alter its molecular structure or target interaction. It is used exclusively as an internal standard for analytical quantification and is not employed in biological activity assays. |
| ln Vivo |
The parent drug Ropivacaine is used in vivo as a local anesthetic via infiltration, epidural, or peripheral nerve block. The labeled analog is used as an internal standard in PK studies to quantify unlabeled ropivacaine in plasma or tissue samples from animals or patients dosed with the therapeutic drug, enabling the determination of exposure and pharmacokinetic parameters.
|
| Enzyme Assay |
As an analytical standard, Ropivacaine-d7 hydrochloride is not used in enzyme/receptor binding assays. A typical LC-MS/MS protocol involves preparing a stock solution of the labeled standard in methanol or acetonitrile, spiking it into calibration standards and quality control samples at a fixed concentration (e.g., 10-100 ng/mL), and monitoring specific mass transitions for the labeled and unlabeled species.
|
| Cell Assay |
This compound is not used in cell-based experiments. In cell culture studies investigating ropivacaine's effects on neuronal cells, the labeled standard may be used as an internal standard for quantifying the parent drug in cell lysates or culture media, enabling studies of cellular uptake, metabolism, and toxicity.
|
| Animal Protocol |
There is no in vivo protocol for the labeled standard alone. In PK studies, animals (e.g., rats or dogs) are administered unlabeled ropivacaine via an appropriate route (IV, epidural, or local infiltration). Blood samples are collected over time, and the deuterated internal standard is added during sample processing to quantify the parent drug by LC-MS/MS in the range of 0.5-3000 ng/mL.
|
| ADME/Pharmacokinetics |
PK properties of the parent drug: Ropivacaine has a half-life of approximately 1.5-2 hours in adults, high plasma protein binding (~94%), and is extensively metabolized by CYP1A2 and CYP3A4. The labeled standard is formulated in organic solvents (e.g., methanol) for analytical use only, not for in vivo administration.
|
| Toxicity/Toxicokinetics |
The toxicity of Ropivacaine-d7 hydrochloride is expected to be similar to the unlabeled drug, which at high doses can cause central nervous system (CNS) toxicity (seizures) and cardiovascular depression. However, at the trace concentrations used as an internal standard, no toxicity is expected. Standard chemical safety precautions should be followed.
|
| References |
|
| Additional Infomation |
Ropivacaine-d7 hydrochloride is a valuable tool for bioanalysis of local anesthetics. The parent drug is a single enantiomer (S-enantiomer) with a better safety profile than bupivacaine, offering a greater degree of sensory-motor differentiation. The deuterated internal standard is used in LC-MS/MS methods validated according to EMA and FDA guidelines for the quantification of free and total ropivacaine in human plasma.
|
| Molecular Formula |
C17H20D7CLN2O
|
|---|---|
| Molecular Weight |
317.91
|
| Exact Mass |
317.225
|
| CAS # |
1217667-10-1
|
| Related CAS # |
Ropivacaine;84057-95-4;Ropivacaine hydrochloride monohydrate;132112-35-7;Ropivacaine hydrochloride;98717-15-8;Ropivacaine mesylate;854056-07-8;Ropivacaine-d7;684647-62-9;(Rac)-Ropivacaine-d7;1392208-04-6
|
| PubChem CID |
46782899
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.895
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
308
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl
|
| InChi Key |
NDNSIBYYUOEUSV-JRDUKJLFSA-N
|
| InChi Code |
InChI=1S/C17H26N2O.ClH/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3;/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20);1H/t15-;/m0./s1/i1D3,4D2,11D2;
|
| Chemical Name |
(2S)-N-(2,6-dimethylphenyl)-1-(1,1,2,2,3,3,3-heptadeuteriopropyl)piperidine-2-carboxamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1455 mL | 15.7277 mL | 31.4554 mL | |
| 5 mM | 0.6291 mL | 3.1455 mL | 6.2911 mL | |
| 10 mM | 0.3146 mL | 1.5728 mL | 3.1455 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
